At Fosun Health, bladder cancer diagnosis is not just about “finding cancer”—it is about determining how deep it has invaded (non-muscle-invasive vs. muscle-invasive), identifying molecular drivers, and designing a plan that preserves your bladder, your sexual function, and your quality of life. Our streamlined pathway delivers answers within days:
- Urinalysis & Urine Cytology: Detects blood and abnormal cancer cells shed from the bladder lining.
- Urine Biomarkers: FDA-approved tests (UroVysion, NMP22, Cxbladder) improve sensitivity for detecting high-grade tumors.
- CT Urography (CTU): The gold standard for evaluating the entire urinary tract (kidneys, ureters, bladder) and detecting upper tract tumors or metastases.
- MRI of Bladder (VI-RADS): Accurately distinguishes non-muscle-invasive (T1) from muscle-invasive (T2+) disease—critical for treatment planning.
- PET-CT: Detects lymph node and distant metastases for staging.
- White Light & Narrow Band Imaging (NBI) Cystoscopy: Visualizes the entire bladder lining. NBI improves detection of flat or small tumors (carcinoma in situ).
- Transurethral Resection of Bladder Tumor (TURBT): Both diagnostic and therapeutic. Removes all visible tumor tissue to confirm stage and grade.
CTU or PET-CT: Determines if cancer has spread to lymph nodes, bones, liver, or lungs.
Using NGS (Next-Generation Sequencing), we analyze FGFR mutations (FGFR2/3), HER2, MSI/dMMR, TMB, NTRK fusions, and over 300 cancer-related genes. This determines whether your tumor will respond to FGFR inhibitors (erdafitinib), HER2-targeted ADCs (disitamab vedotin, enfortumab vedotin), immunotherapy (pembrolizumab for MSI-H/dMMR or high TMB), or clinical trials of novel bispecific antibodies—ensuring your treatment is matched to your tumor’s unique biology, not a generic protocol.
